Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 3
2001 3
2002 3
2003 4
2004 2
2005 2
2006 2
2009 2
2010 3
2011 1
2012 5
2013 4
2015 5
2016 3
2017 5
2019 1
2020 5
2021 7
2022 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.
Catto JWF, Tran B, Rouprêt M, Gschwend JE, Loriot Y, Nishiyama H, Redorta JP, Daneshmand S, Hussain SA, Cutuli HJ, Procopio G, Guadalupi V, Vasdev N, Naini V, Crow L, Triantos S, Baig M, Steinberg G; THOR-2 Cohort 1 Investigators. Catto JWF, et al. Ann Oncol. 2024 Jan;35(1):98-106. doi: 10.1016/j.annonc.2023.09.3116. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871701 Free article. Clinical Trial.
The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer.
Passarelli A, Ventriglia J, Pisano C, Cecere SC, Napoli MD, Rossetti S, Tambaro R, Tarotto L, Fiore F, Farolfi A, Bartoletti M, Pignata S. Passarelli A, et al. Among authors: tambaro r. Front Oncol. 2023 Jan 13;12:1088962. doi: 10.3389/fonc.2022.1088962. eCollection 2022. Front Oncol. 2023. PMID: 36713525 Free PMC article.
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial.
Vignani F, Tambaro R, De Giorgi U, Giannatempo P, Bimbatti D, Carella C, Stellato M, Atzori F, Aieta M, Masini C, Hamzaj A, Ermacora P, Veccia A, Scandurra G, Gamba T, Ignazzi G, Pignata S, Di Napoli M, Lolli C, Procopio G, Pierantoni F, Zonno A, Santini D, Di Maio M; Meet-URO12 Investigators. Vignani F, et al. Among authors: tambaro r. Eur Urol. 2023 Jan;83(1):82-89. doi: 10.1016/j.eururo.2022.09.025. Epub 2022 Oct 8. Eur Urol. 2023. PMID: 36216658 Clinical Trial.
Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer.
Passarelli A, Pisano C, Cecere SC, Di Napoli M, Rossetti S, Tambaro R, Ventriglia J, Gherardi F, Iannacone E, Venanzio SS, Fiore F, Bartoletti M, Scognamiglio G, Califano D, Pignata S. Passarelli A, et al. Among authors: tambaro r. Front Immunol. 2022 Sep 2;13:953115. doi: 10.3389/fimmu.2022.953115. eCollection 2022. Front Immunol. 2022. PMID: 36119020 Free PMC article. Review.
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group).
Bersanelli M, Mazzaschi G, Giannatempo P, Raggi D, Farè E, Maruzzo M, Basso U, De Giorgi U, Vignani F, Banna GL, Stellato M, Tambaro R, Naglieri E, Losanno T, Procopio G, Pignata S, Necchi A, Buti S. Bersanelli M, et al. Among authors: tambaro r. Immunotherapy. 2022 Feb;14(2):107-114. doi: 10.2217/imt-2021-0109. Epub 2021 Nov 17. Immunotherapy. 2022. PMID: 34784782
Oligometastatic prostate cancer treatment.
Rossetti S, Di Napoli M, Pisano C, C Cecere S, Tambaro R, Ventriglia J, Passarelli A, Iovane G, Feroce F, Lastoria S, Di Gennaro F, Muto P, Borzillo V, Di Franco R, Perdonà S, Quarto G, Pignata S. Rossetti S, et al. Among authors: tambaro r. Future Oncol. 2021 Oct;17(29):3893-3899. doi: 10.2217/fon-2021-0126. Epub 2021 Jul 23. Future Oncol. 2021. PMID: 34296622
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
Bersanelli M, Buti S, Cortellini A, Bandini M, Banna GL, Pederzoli F, Farè E, Raggi D, Giannatempo P, De Giorgi U, Basso U, Losanno T, Santini D, Mucciarini C, Tucci M, Tambaro R, Farnesi A, Caffo O, Veccia A, Naglieri E, Briganti A, Procopio G, Pignata S, Necchi A. Bersanelli M, et al. Among authors: tambaro r. Clin Med Insights Oncol. 2021 Jul 8;15:11795549211021667. doi: 10.1177/11795549211021667. eCollection 2021. Clin Med Insights Oncol. 2021. PMID: 34290538 Free PMC article.
60 results